Dr. Hermann Allgaier
Dr. Hermann Allgaier was appointed Managing Director of Teva Biotech GmbH (until May 31st, 2016 known as Merckle Biotec GmbH) Ulm, Germany in 2004, a subsidiary of the former Merckle/ratiopharm group devoted to the development and market supply of Biosimilars and innovative New Biological Entities. Since 2010 the company belongs to Teva, a global pharmaceutical company with focus on speciality medicines, generics and OTC s. Dr. Allgaier is also a member of Teva s German executive board. Prior to his commitment to Merckle Biotec Dr. Allgaier acted as Managing Director of LSMW GmbH in Stuttgart (now M+W Group), Germany, an architecture and engineering firm which specialized in Pharmaceuticals and Biopharmaceuticals from 1997 - 2004. He started his carrier in 1985 at the former Dr. Karl Thomae GmbH, a subsidiary of Boehringer Ingelheim. The years 1985 - 1996 were marked by the rapid growth of biopharmaceuticals and the first FDA approval of a biotech multipurpose plant. Dr. Allgaier studied chemistry and specialized in biotechnology at the Eberhard Karls University of Tübingen where he completed his thesis and was distinguished with the Friedrich-Weygand-Award for his work with peptide antibiotics. Dr. Allgaier has made numerous presentations and publications in the area of biopharmaceutical development, manufacturing, compliance and business issues. He serves as a member of the advisory board for several universities and universities of applied sciences with biopharmaceutical focus. Dr. Allgaier is member of the International Association for Pharmaceutical Technology (APV) since 2000 and was head of the focus group Pharmaceutical Biotechnology from 2000-2005. Since 2006 he is a member of the APV board.